Efficacy and Safety of Golimumab in Patients with Non-radiographic Axial Spondyloarthritis: A Withdrawal and Retreatment Study (GO-BACK)
Rheumatology (Oxford) 2023;62(11):3601–3609 doi: 10.1093/rheumatology/kead112
This study highlighted that continued treatment with Golimumab (GLM) QMT or GLM Q2MT was superior to placebo. The GO-BACK study was designed to evaluate the efficacy and safety of golimumab treatment withdrawal in adults with nr-axSpA who demonstrate inactive disease during a 10-month open label GLM run-in.
Overall, GLM QMT was most beneficial in reducing the incidence of disease flares, and improving clinical signs and symptoms of nr-axSpA compared with treatment withdrawal. GLM was generally well tolerated, and safety results were consistent with the known safety profile of GLM.
Keywords:
